Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 4,486 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $5.21, for a total transaction of $23,372.06. Following the completion of the sale, the chief executive officer owned 3,642,481 shares of the company's stock, valued at $18,977,326.01. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Stock Performance

---

---

NASDAQ:SOPH opened at $5.12 on Wednesday. The company has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $4.74. The company has a market cap of $350.67 million, a price-to-earnings ratio of -10.04 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 52 week low of $2.59 and a 52 week high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.

Wall Street Analysts Forecast Growth

Several research firms have commented on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim boosted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Finally, BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, April 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $7.50.

View Our Latest Stock Report on SOPH

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently modified their holdings of SOPH. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth $48,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth $49,000. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth $49,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

Featured Articles

• Five stocks we like better than SOPHiA GENETICS

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].